GLA Iodine Selenium Composition for Fibrocystic Breast Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrocystic breast disease and other breast-related conditions, such as premenstrual or cyclic breast pain, breast cancer, and elevated mammographic breast density, often provide inadequate relief and are associated with significant side effects, limiting their effectiveness and patient compliance.
Innovation Solution
A nutritional composition combining gamma linolenic acid (GLA), iodine, and optionally selenium, administered orally as a single daily product, which enhances breast health by reducing pain and tenderness, mammographic breast density, and the risk of undesirable cell proliferation, while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone-based medications (danazol, bromocriptine, tamoxifen, raloxifene) are prescribed to treat fibrocystic breast disease, then pain relief and symptom management are improved, but side effects increase significantly limiting patient compliance
Solution Approach 1:
The patent combines multiple nutrients (GLA from evening primrose oil, iodine, vitamin E, selenium, and B-complex vitamins) into a single complementary formulation that works synergistically to address fibrocystic breast disease symptoms. This combination approach provides effective pain relief and symptom management while avoiding the severe side effects associated with hormone-based medications, thereby improving patient compliance and tolerability.
Solution Approach 2:
The patent replaces expensive, long-term hormone-based medications with a more affordable, natural nutrient combination that can be taken as needed. The complementary formulation uses readily available nutrients that accumulate beneficial effects over time without causing the severe, limiting side effects of prescription hormones, making it accessible and sustainable for long-term patient use.
2Object-affected harmful factors
If non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, ketoprofen) are used to treat mastalgia, then pain relief is provided, but the relief is often inadequate for moderate to severe pain
Solution Approach 1:
The patent combines gamma linolenic acid (GLA) with iodine, vitamin E, selenium, and B-complex vitamins to create a synergistic formulation that addresses the inflammatory and hormonal imbalances underlying mastalgia. This multi-nutrient approach provides more comprehensive and adequate pain relief for moderate to severe cases compared to single-ingredient NSAIDs, while avoiding their limitations in effectiveness.
3Ease of operation
If a single daily nutritional product containing GLA, iodine, and selenium is administered, then patient compliance improves, but the complexity of formulation increases
Solution Approach 1:
The patent consolidates multiple essential nutrients (GLA, iodine, selenium, vitamin E, and B-complex vitamins) into a single complementary formulation that can be administered once daily. This merger of multiple active ingredients into one product simplifies patient compliance while the synergistic interactions between components enhance therapeutic effectiveness for fibrocystic breast disease management.
Solution Approach 2:
The single daily product serves multiple functions simultaneously: providing anti-inflammatory effects (GLA), supporting thyroid function (iodine and selenium), protecting cell membranes (vitamin E), and supporting nerve function (B-complex vitamins). This multi-functional approach addresses various aspects of fibrocystic breast disease through one comprehensive formulation, improving compliance without sacrificing therapeutic breadth.
Data Source
AI summary
Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 μg selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.